NASDAQ: MRNSMarinus Pharmaceuticals Inc Stock
$1.44+0.00 (+0%)
Updated Apr 24, 2024
MRNS Price
$1.44
Fair Value Price
N/A
Market Cap
$78.69M
52 Week Low
$1.11
52 Week High
$11.26
P/E
-0.55x
P/B
4.69x
P/S
18.85x
PEG
N/A
Dividend Yield
N/A
Revenue
$30.99M
Earnings
-$141.41M
Gross Margin
93.8%
Operating Margin
-406.75%
Profit Margin
-456.3%
Debt to Equity
9.19
Operating Cash Flow
-$118M
Beta
1.35
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
MRNS Overview
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, tuberous sclerosis complex, depressive disorders, and Lennox-Gestaut Syndrome. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how MRNS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MRNS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MRNS is good value based on its book value relative to its share price (4.69x), compared to the US Biotechnology industry average (5.86x)
P/B vs Industry Valuation
MRNS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more MRNS due diligence checks available for Premium users.
Be the first to know about important MRNS news, forecast changes, insider trades & much more!
MRNS News
Valuation
MRNS fair value
Fair Value of MRNS stock based on Discounted Cash Flow (DCF)
Price
$1.44
Fair Value
-$4.58
Undervalued by
131.45%
MRNS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MRNS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.55x
Industry
15.69x
Market
41.27x
MRNS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.69x
Industry
5.86x
MRNS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MRNS's financial health
Profit margin
Revenue
$7.2M
Net Income
-$41.8M
Profit Margin
-580.9%
MRNS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
MRNS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$170.9M
Liabilities
$154.1M
Debt to equity
9.19
MRNS's short-term assets ($165.25M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MRNS's short-term assets ($165.25M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MRNS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
MRNS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$27.0M
Investing
$6.5M
Financing
$661.0k
MRNS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MRNS vs Biotech Stocks
Marinus Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.